Sign In
Buy HZNP
$116.30
+0 (+0%)
At Close: Jan 04, 2024
Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 25'th Nov 2020
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conferences in December: 2020 Evercore ISI HealthCONx Conference Dat
DUBLIN & SAN DIEGO--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives Hori
Top Healthcare Stocks for December 2020
01:03pm, Thursday, 19'th Nov 2020
These are the healthcare stocks with the best value, fastest growth, and most momentum for December 2020.
5 Stocks Set to Score From MSCI Index Rebalancing
10:45am, Friday, 13'th Nov 2020
Most experienced investors are well aware of the major indexes that compose the equity markets.
Horizon Therapeutics CEO On Success Of Key Drug Tepezza, Acquisition Plans
11:37am, Tuesday, 03'rd Nov 2020
Horizon Therapeutics on Monday reported a solid quarter with big beats on the top and bottom lines and raised its guidance, thanks in large part to its thyroid eye disease drug Tepezza, which just got
Investing Strategies: Horizon Therapeutics CEO, Chegg CFO, O'Neil Investment Strategist Insight
11:34am, Tuesday, 03'rd Nov 2020
On this episode, IBD's Alissa Coram speaks with executives of two IBD 50 members in the wake of their quarterly earnings reports. First, Horizon Therapeutics CEO Tim Walbert shares insights into what
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced data from the first randomized controlled clinical trial (RCT) of KRYSTEXXA (pegloticase injection) concomitantly used
Horizon Therapeutics PLC (HZNP) CEO Timothy Walbert on Q3 2020 Results - Earnings Call Transcript
01:22pm, Monday, 02'nd Nov 2020
Horizon Therapeutics PLC (HZNP) CEO Timothy Walbert on Q3 2020 Results - Earnings Call Transcript
Horizon Therapeutics Easily Tops Views, Hikes Outlook, But HZNP Stock Falls
08:47am, Monday, 02'nd Nov 2020
Horizon Therapeutics posted third-quarter earnings and sales that easily topped Wall Street expectations and the maker of drugs to treat rare diseases hiked its outlook, but HZNP stock fell. The post
Chicago Tribune Names Horizon Therapeutics a 2020 Top Workplace for the Sixth Consecutive Year
09:15am, Friday, 30'th Oct 2020
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of the Chicago Tribune's Top Workplaces 2020, ranking number two out of other midsize compan
AGC Biologics and Horizon Therapeutics plc Expand Partnership
03:00pm, Thursday, 29'th Oct 2020
SEATTLE, Oct. 29, 2020 /PRNewswire/ -- AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced that its partnership with Horizon Therape
Were Hedge Funds Right About Crowding Into Horizon Therapeutics (HZNP)?
10:04pm, Monday, 26'th Oct 2020
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in ( Recession is Imminent: We Need A Travel Ban NOW
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2020 Update
10:49am, Friday, 11'th Sep 2020
Halvorsen's 13F portfolio value increased from $19.21B to $23.14B. The number of positions increased from 64 to 71.
Tracking John Paulson's Paulson & Company Portfolio - Q2 2020 Update
09:49am, Wednesday, 19'th Aug 2020
John Paulson’s 13F portfolio value increased from $2.62B to $3.13B this quarter. Paulson & Company's largest three positions are Bausch Health, Horizon Therapeutics, and SPDR Gold ETF.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the closing of its underwritten public offering of 13,570,000 of its ordinary shares at a price to the public of $71.00 per share. This includes
